Dr. Dreyling on Key Efficacy Results From the TRIANGLE Study in MCL


Martin Dreyling, MD, discusses key efficacy results from the phase 3 TRIANGLE study in mantle cell lymphoma.

Martin Dreyling, MD, associate professor of medicine, University of Munich, head of the Lymphoma Program in the Department of Internal Medicine III, University Hospital of Munich (LMU), Germany, discusses key efficacy results from the phase 3 TRIANGLE study (NCT02858258) in mantle cell lymphoma (MCL).

The open-label trial evaluated the addition of ibrutinib (Imbruvica) to standard induction chemoimmunotherapy followed by autologous stem cell transplantation (ASCT) and fixed 2-year maintenance for young patients with mantle cell lymphoma. Induction therapy consisted of R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone)/R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin).

Patients were randomly assigned to 1 of 3 treatment arms including induction/maintenance ibrutinib plus induction chemoimmunotherapy with ASCT and, ibrutinib plus induction chemoimmunotherapy and maintenance ibrutinib without ASCT, or a standard arm of induction therapy and ASCT alone.

A head-to-head comparison of all treatment arms showed a 3-year failure-free survival (FFS) rate of 72% in the standard arm, 86% in the ibrutinib without ASCT arm, and 88% in the ibrutinib with ASCT arm, Dreyling states. Although overall survival (OS) data are not fully mature, the 3-year OS rates showed that patients receiving the ibrutinib induction/maintenance experience improved outcomes compared to patients receiving standard ASCT alone.

Moreover, investigators originally postulated that ASCT would retain its status as the current standard of care if it demonstrated superiority over ibrutinib, Dreyling continues. However, ibrutinib-containing arms demonstrated improved FFS, clinically meaningful benefit, and OS benefit regardless of whether ASCT was administered, he says. 

Although no verdict on the role of ASCT has been reached, the ibrutinib without ASCT regimen was also associated with decreased toxicity, implying that ASCT may no longer be considered a standard treatment component for this patient population.

Related Videos
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute